BeiGene
BeiGene is a life sciences biotechnology company.
BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
AI Pharmaceutical R&D Company DP Technology Raises New Round of Over CNY 700 Mn Financing
EqualOcean has learned that DP Technology(深势科技), an AI pharmaceutical research company, has recently successfully completed a funding round of over CNY 700 million. Investors in this round include Zhongyuan Capital(众源资本), MSA Capital(和玉资本), Loyal Valley Capital(正心谷资本), Evergreen Scitech Delta(深势科技), and many other industry-specific investors, with Lighthouse Capital(光源资本) serving as the exclusive financial advisor.
Aug 22, 2023 03:34 PM
Chinese Sports Tech Brand Keep Officially Lists on the Hong Kong Stock Exchange
On July 12, 2023, Beijing-based Beijing Calorie Technology Co., Ltd (hereinafter referred to as "Keep") was officially listed on the Hong Kong Stock Exchange (HKEx) under the stock code "3650" at an offering price of HKD 28.92 per share.
Jul 18, 2023 06:27 PM
Chinese Firm Pyrotech Therapeutics Completes CNY 700 Mn Series A Round of Financing
Currently, China's innovation resources in the field of biomedicine are mainly concentrated in the pharmaceutical industry, with very few companies focusing on drug development and innovation. Pyrotech (Beijing) Biotechnology Co., Ltd. pioneered the biotechnology platform and is committed to building a global leading Chinese biotechnology company.
Jul 17, 2023 06:22 PM